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Drugs for Parkinson’s disease: Levodopa is still the gold standard
Parkinson’s disease (PD) is a global afﬂ  iction which occurs in all ethnic groups and 
socioeconomic classes, with estimated incidences ranging from 16–19 per 100,000 
people per year and crude prevalence rates as high as 160 per 100,000 people per year 
(WHO/WFN 2004). It was recently estimated that there were over 1 million PD patients 
in Western Europe and the USA in 2005, and this number was expected to double 
by 2030 with accompanying dramatic rises in the numbers in developing countries 
(Dorsey et al 2007). Patients have both disabling motor symptoms and distressing 
non-motor features like depression and anxiety. Pharmacotherapy for PD has been 
available since the 1950s in the form of anticholinergic drugs, which are of limited 
efﬁ  cacy and carry a high burden of gastrointestinal and neuropsychiatric side effects 
(Katzenschlager 2007). More effective treatment arrived in the early 1960s with the 
ﬁ  rst clinical trials of levodopa (Birkmayer and Horneykiewicz 1961), and there are 
now many different formulations and variants on the levodopa theme (Lundqvist 2007) 
as well as a plethora of selective dopamine agonists of the ergoline and nonergoline 
type (Pinder 2007). The only exception to the dopamine theme has been selegiline, 
an irreversible inhibitor of monoamine oxidase type B (MAO-B), which ﬁ  nds use in 
both PD and major depressive disorder (Lee and Chen 2007).
In this issue of Neuropsychiatric Disease and Treatment, a number of issues con-
cerning the drug treatment of PD are reviewed. Nayak and Henchcliffe (2008) discuss 
the merits of the newly approved MAO-B inhibitor, rasagiline, which shares with sele-
giline a potential for neuroprotective effects but does lack the latter’s amphetamine and 
methamphetamine metabolites. Time will tell whether rasagiline is a worthy addition 
to the PD armamentarium, but early clinical results are very promising. Thus, rasagi-
line as monotherapy has proved effective, safe and well tolerated in early PD, while 
large trials in advanced PD suggest that when given adjunctively with levodopa it can 
signiﬁ  cantly decrease ‘off’ time. Many PD patients suffer ‘on’ and ‘off’ periods during 
ongoing dopaminergic pharmacotherapy, when their motor symptoms either respond 
or return, the ‘off’ being attributed to the deep troughs in delivery of levodopa to the 
brain arising from the short plasma half-life of conventional levodopa formulations. 
Indeed the ‘off’ time with its associated motor complications has led to both physician 
caution and patient reluctance to use levodopa, and its various combinations with dopa 
decarboxylase inhibitors (DDCI), as the initial treatment for newly diagnosed early 
PD (Antonini et al 2008; Brooks 2008). Dopamine agonists have become, almost by 
default, the drugs of choice for front-line treatment of early PD. However, a number 
of large, well controlled, long-term clinical trials have consistently demonstrated the 
substantial superiority of the symptomatic control offered by conventional levodopa 
formulations compared with dopamine agonists. Levodopa remains the gold standard 
of PD therapy (Lundqvist 2007; Antonini et al 2008; Brooks 2008).
Levodopa is metabolized via two peripheral pathways before it can reach the brain, 
one to dopamine involving the enzyme dopa decarboxylase (DDC) and the other to 
3-O-methyldopa involving another enzyme catechol-O-methyltransferase (COMT). 
Inhibitors of DDC such as carbidopa have long been available and were introduced 
many years ago into PD treatment in combination with levodopa (Antonini et al 2008; 
Brooks 2008). COMT inhibition is a more recent target, and two agents have been 
introduced, tolcapone (Antonini et al 2008) and entacapone (Brooks 2008), as add-on Neuropsychiatric Disease and Treatment 2008:4(1) ii
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therapies to conventional levodopa and levodopa/carbidopa 
combinations. Both agents seem to signiﬁ  cantly increase 
‘on’ time in PD patients who are experiencing reemergence 
of motor symptoms, they afford greater functionality than 
conventional levodopa and combinations alone, and they are 
generally well tolerated. It is suggested that patients who 
experience motor ﬂ  uctuations despite ongoing treatment 
with conventional levodopa, dopamine agonists or MAO-
B inhibitors should receive a trial with a COMT inhibitor 
and certainly before levodopa infusion or neurosurgery are 
considered as last resort strategies.
Many PD patients experience neuropsychiatric illnesses 
such as anxiety and depression. Depression is particularly 
difﬁ  cult to diagnose in PD patients because of the overlap of 
many of the cognitive, motor and somatic symptoms (Looi 
et al 2005; Frisina 2008). PD patients, even when suffering 
from affective disturbances, are more likely to complain about 
their burden of motor disability. Nevertheless, depression 
seems to occur in about 30%–40% of PD patients, of whom 
only one-ﬁ  fth receive any form of antidepressant treatment. In 
this issue, Frisina and her colleagues (2008) discuss the health 
risks, etiology, and treatment options for depression in PD 
patients. It seems that conventional treatments are effective, 
and they recommend a multidisciplinary approach combining 
pharmacotherapy, psychotherapy, and psychoeducation.
PD is a complex disease but there are many therapeutic 
possibilities to relieve the burden of both the motor and some 
of the nonmotor symptoms. All of the current pharmaco-
therapies are symptomatic, and only neurosurgery goes to the 
heart of the neuropathology. However, most PD patients can 
be reliably maintained on a judiciously tailored and regularly 
monitored set of medications. Advances in our understanding 
of the pathogenesis of the disease, particularly the rapidly 
expanding ﬁ  eld of PD genetics, may lead to more speciﬁ  c 
and potentially disease modifying modalities in the future. 
Whatever, on the basis of current and extensive evidence in 
clinical trials and despite its many shortcomings, levodopa 
in its several forms remains the gold standard of efﬁ  cacy and 
effectiveness in PD therapeutics.
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